References
- Ward PS, Patek J, Wise DR, et al The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydrozyglutarate. Cancer Cell 2010;17:225–234.
- Sjoblom T, Jones S, Wood LD, et al The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268–274.
- Parsons DW, Jones S, Zhang X, et al An integrated genomic analysis of human glioblastoma multiforme Science 2008;321: 1807–1812.
- Yan H, Parsons DW, Jin G, et al IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–773.
- Mardis ER, Ding L, Dooling DJ, et al Recurring mutations found by sequencing an acute myeloid leukemia genome. New Engl J Med 2009;361:1058–1066.
- Marcucci G, Maharry K, Wu YZ, et al IDH1 and IDH2 gene mutations indentify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:2348–2355.
- Thol F, Damm F, Wagner K, et al Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010;116:614–616.
- Paschka P, Schlenk RF, Gaidzik VI, et al IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28: 3636–3643.
- Abbas S, Lugthart S, Kavelaars FG, et al Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia (AML): prevalence and prognostic value. Blood2010 Jun 10 [Epub ahead of print].
- Jeziskova I, Razga F, Bajerova M, Racil Z, Mayer J, Dvorakova D. IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status. Leuk Lymphoma 2010;51:2285–2287.